Herein, we report an optimized radiopharmaceutical, [68Ga]Ga-BL31, with improved tumor-to-kidney contrast ratios, with superior imaging capabilities as compared to the leading clinical CXCR4-targeting radiotracer, [68Ga]Ga-Pentixafor. This evidence concerns the gene CXCR4 and neoplasm.